Hinge Health, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

HNGE$122.19+5.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and par value data)

September 30, 2026 · December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$211,553		$207,995
Short-term marketable securities	83,102		155,867
Accounts receivable, net of allowance for credit losses of $7,647 and $6,092 as of September 30, 2026 and December 31, 2025, respectively	148,532		66,061
Deferred commissions	46,599		31,344
Inventory	19,186		15,636
Prepaid expenses and other current assets	58,891		57,001
Total current assets	567,863		533,904
Long-term marketable securities	59,542		113,172
Goodwill	113,030		64,096
Intangible assets, net	68,328		2,512
Property, equipment and software, net	13,989		10,490
Operating lease right-of-use assets	33,317		6,861
Other assets	18,012		13,726
Total assets	$874,081		$744,761
Liabilities, redeemable convertible preferred stock and stockholders’ equity
Current liabilities:
Accounts payable and accrued liabilities	$80,816		$57,331
Operating lease liabilities	4,721		4,223
Deferred revenue	459,174		300,855
Total current liabilities	544,711		362,409
Operating lease liabilities, noncurrent	29,157		3,816
Deferred tax liabilities	795		—
Total liabilities	574,663		366,225
Commitments and contingencies (Note 7)
Redeemable convertible preferred stock:
Redeemable convertible preferred stock, $0.00001 par value; 4,330,341 shares of Series E authorized as of September 30, 2026 and December 31, 2025; 0 shares and 2,581,837 shares of Series E preferred stock issued and outstanding as of September 30, 2026 and December 31, 2025, respectively; aggregate liquidation preference of $0 and $200,000 as of September 30, 2026 and December 31, 2025, respectively	—		199,874
Stockholders’ equity:
Class A common stock, $0.00001 par value: 1,000,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 65,752,330 shares and 55,883,690 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	—		—
Class B common stock, $0.00001 par value: 120,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 15,465,522 shares and 23,287,614 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	—		—
Additional paid-in capital	1,215,118		1,229,678
Accumulated other comprehensive loss	(921)	(20)
Accumulated deficit	(914,779)		(1,050,996)
Total stockholders’ equity	299,418		178,662
Total liabilities, redeemable convertible preferred stock and stockholders’ equity	$874,081		$744,761

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.